Not Signed In -
Fulvestrant Other Information |
Faslodex |
Fulvestrant, also known as ICI 182,780, is a drug treatment of hormone receptor positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor.[1] It is administered as a once-monthly injection. Fulvestrant is marketed by AstraZeneca with the brand name Faslodex. ...
Wikipedia - [full article]
From the WEST scientific·clinical |
From the EAST traditional·alternative |
|
|
|
|
Faslodex Consumer Information
... FASLODEX is used to treat hormone receptor positive breast cancer in postmenopausal women whose disease has spread after treatment with antiestrogens, primarily tamoxifen. Postmenopausal women are wom...
Source: U.S. Food and Drug Administration
|
|
Resources
- Faslodex (Drug Digest)
- Faslodex Consumer Information (U.S. Food and Drug Administration)
email this page
print this page
bookmark this page
feedback on this page
